5 Key Takeaways

• 1

  Tenofovir amibufenamide (TMF) demonstrated effectiveness comparable to tenofovir disoproxil fumarate (TDF) in treating chronic hepatitis B.

• 2

  TMF showed improved renal safety and no impact on lipid profiles compared to TDF in a multicenter cohort study.

• 3

  In treatment-naive patients, TMF achieved virologic response rates of 42.86% at 24 weeks and 90.48% at 48 weeks.

• 4

  Among treatment-experienced patients, TMF achieved virologic response rates of 83.1% at 24 weeks and 91.55% at 48 weeks.

• 5

  Statistical analysis indicated significant differences in ALT normalization rates between local and AASLD 2018 standards.